HLS-Development of a cardiac ischemia model in an organ-on-a-chip platform

HLS-在器官芯片平台中开发心脏缺血模型

• 批准号: 10395312
• 负责人: James J Hickman
• 金额: $ 85.48万
• 依托单位: HESPEROS, LLC
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10395312
• 关键词: Acute; Affect; Award; Biological Markers; Biological Models; Biological Products; Biomedical Engineering; Blood Vessels; Cardiac; Cardiac Myocytes; Cell Culture Techniques; Cells; Cellular biology; Characteristics; Chemicals; Chronic; Coculture Techniques; Competence; Contracts; Cosmetics; Development; Devices; Drug Compounding; Drug Costs; Drug toxicity; Electrocardiogram; Electrophysiology (science); Endothelial Cells; Evaluation; Event; Exhibits; Generations; Goals; Grant; Health; Heart failure; Housing; Human; In Situ; In Vitro; Investigation; Ischemia; Lead; Legal patent; Letters; Liquid substance; Liver; Measurement; Measures; Mechanics; Membrane Potentials; Microelectrodes; Microfluidics; Modeling; Monitor; Motion; Muscle; Muscle Contraction; Muscle function; Myocardial Infarction; Myocardial Ischemia; Neurons; Organ; Output; Pattern; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Phase; Phenotype; Philosophy; Physiological; Physiology; Preclinical Testing; Process; Production; Proteins; Protocols documentation; Publishing; Pump; Recovery; Reperfusion Injury; Reperfusion Therapy; Rest; Serum; Services; Small Business Innovation Research Grant; Smooth Muscle; Smooth Muscle Myocytes; Stress; Surface; System; Techniques; Testing; Therapeutic; Time; Tissues; Toxic effect; Validation; Vascular Smooth Muscle; base; body on a chip; body system; cantilever; cardioprotection; clinical development; commercialization; constriction; cost; design; drug candidate; drug development; drug discovery; drug testing; experience; experimental study; heart electrical activity; heart function; hemodynamics; human model; in vivo; induced pluripotent stem cell; induced pluripotent stem cell derived cardiomyocytes; instrumentation; microphysiology system; non-invasive monitor; novel; operation; organ on a chip; patch clamp; prevent; prophylactic; response; restoration; screening; sensor; simulation; skills; small molecule

Project Summary Our overall strategy for Hesperos is to utilize microphysiological systems in combination with functional readouts to establish platforms capable of sophisticated analysis of chemicals and drug candidates for toxicity and efficacy during pre-clinical testing, with initial emphasis on predictive toxicity. This is a service based company and is developing low-cost in vitro systems utilizing a novel “pumpless” microphysiological platform described in US Patent 8,748,180B2. The commercialization potential of our system has been validated by the award of a Phase IIB SBIR to apply advanced manufacturing techniques to increase output and lower cost of production. The pumpless integrated system, using a rocking motion to pump the serum-free cellular medium, reduces the complexity and cost of the fluidic circuit design and simplifies set-up and operation of the device. Hickman has developed microelectrode arrays and cantilever systems that are integrated on chip for noninvasive electronic and mechanical readouts. We have detailed an in vitro cardiac system where the two main components of function, electrical conduction and muscle force, have been reproduced in vitro. The independent measurement of these two key variables allows a detailed description of a compound’s effect on overall cardiac function and is currently being used under contract by multiple companies. Because we can measure these functional outputs independently, we can also use these readouts to give ideas on mechanism of action of a compound. We have adapted this chip based system into a platform for testing cardiac ischemia and reperfusion as published in APL Bioengineering that demonstrated an investigational compound effectively reduced ischemia/reperfusion damage in vitro. The human iPSC cardiac cells used in this device were shown to reach some aspects of functional maturation as primarily evidenced by patch clamp electrophysiological measurements indicating resting membrane potentials of -85 mV or better. We will expand this system by integrating a hemodynamic module of vascular smooth muscle cells and microvascular endothelial cells with the microfluidic system and develop continuous monitoring instrumentation. This cardiac organ-on-a-chip platform will be validated by screening compounds that act either directly on the cardiac cells or affect hemodynamics, and will be used to screen investigational compounds from our pharma partners. A microphysiological system will be developed with continuous readouts for smooth muscle cell contraction, cardiac electrical and mechanical function, fitted with environmental sensors, and integrated with an environmental chamber for inducing ischemia. We will first optimize and validate environmental conditions and protocols for inducing and measuring cardiac ischemic damage, followed by validation with ischemia drugs with published in vivo and in vitro results. The uniqueness will be the combination of Hickman’s functional modules with Shuler’s “pumpless” system, as well as continuous measurement of both cardiac and hemodynamic effects. Our team contains all of the skill sets required to construct, evaluate and commercialize the integrated system and associated components to achieve the goals.

项目摘要 我们对Hesperos的总体策略是利用微生理系统与功能读数相结合 建立能够对化学品和候选药物的毒性和功效进行复杂分析的平台 在临床前试验期间，最初强调预测毒性。这是一家以服务为基础的公司， 开发低成本的体外系统，该系统利用美国专利No.5，644，500中描述的新型“无泵”微生理学平台， 专利8，748，180 B2。我们的系统的商业化潜力已经得到了验证， IIB SBIR将采用先进的制造技术，以提高产量和降低生产成本。的 无泵集成系统使用摇摆运动泵送无血清细胞培养基， 降低了流体回路设计的复杂性和成本，并简化了装置的设置和操作。希克曼有 开发了微电极阵列和悬臂梁系统，集成在芯片上，用于非侵入性电子 和机械读数。我们详细介绍了体外心脏系统，其中两个主要组成部分， 功能，电传导和肌肉力量，已经在体外重现。独立测量 这两个关键变量允许详细描述化合物对整体心脏功能的影响， 目前正由多家公司签约使用。因为我们可以测量这些功能输出 独立地，我们也可以使用这些读数来给出化合物作用机制的想法。我们有 将该基于芯片的系统改编成用于测试心脏缺血和再灌注的平台，如APL上所发表的 生物工程证明了一种研究化合物有效地减少了缺血/再灌注 体外损伤。在该装置中使用的人iPSC心脏细胞显示出达到以下的某些方面： 主要通过膜片钳电生理测量证明的功能成熟， 静息膜电位为-85 mV或更好。我们将通过集成血流动力学来扩展该系统 血管平滑肌细胞和微血管内皮细胞与微流体系统的模块， 开发连续监测仪器。该心脏器官芯片平台将通过以下方式进行验证： 筛选直接作用于心脏细胞或影响血液动力学的化合物，并将用于 从我们的制药合作伙伴那里筛选试验性化合物。将开发一个微生理系统， 平滑肌细胞收缩、心脏电和机械功能的连续读数，配有 环境传感器，并与环境室集成用于诱导局部缺血。我们将首先 优化和验证诱导和测量心脏缺血的环境条件和方案 损伤，然后用已发表的体内和体外结果验证缺血药物。唯一性 将是希克曼的功能模块与Shampoo的“无泵”系统相结合，以及连续 测量心脏和血液动力学效应。我们的团队拥有所有必要的技能， 建设、评估和商业化综合系统和相关组件，以实现目标。